Published in Oncotarget on September 29, 2016
Prediction of mammalian microRNA targets. Cell (2003) 53.70
Identification of tissue-specific microRNAs from mouse. Curr Biol (2002) 34.55
The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell (2008) 7.26
Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology (2006) 7.06
Roles for microRNAs in conferring robustness to biological processes. Cell (2012) 6.32
MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A (2005) 5.54
Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 5.24
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 4.91
Evolution of the cancer stem cell model. Cell Stem Cell (2014) 4.38
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol (2008) 4.09
MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A (2007) 3.92
Small RNAs: classification, biogenesis, and function. Mol Cells (2005) 3.59
MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood (2008) 3.50
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A (2008) 3.13
Awakening dormant haematopoietic stem cells. Nat Rev Immunol (2010) 2.88
NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci U S A (2011) 2.74
microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med (2010) 2.68
MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci U S A (2010) 2.53
MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci U S A (2010) 2.40
Metabolic requirements for the maintenance of self-renewing stem cells. Nat Rev Mol Cell Biol (2014) 2.36
Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell (2008) 2.35
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell (2013) 2.33
The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood (2010) 2.33
MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci U S A (2010) 2.29
Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res (2000) 1.94
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res (2005) 1.94
The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res (2010) 1.88
MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc Natl Acad Sci U S A (2010) 1.82
Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood (2012) 1.80
MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest (2012) 1.77
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood (2012) 1.77
MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood (2012) 1.75
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood (2007) 1.61
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2010) 1.59
miR-29a maintains mouse hematopoietic stem cell self-renewal by regulating Dnmt3a. Blood (2015) 1.56
Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol (2010) 1.51
Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res (2008) 1.49
MiR-125 in normal and malignant hematopoiesis. Leukemia (2012) 1.41
MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene (2011) 1.35
Attenuation of miR-126 activity expands HSC in vivo without exhaustion. Cell Stem Cell (2012) 1.35
Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood (2012) 1.31
Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res (2007) 1.27
Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation. Oncogene (2011) 1.16
MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets. Oncogene (2014) 1.16
miR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia. Mol Biol Rep (2011) 1.15
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Res (2015) 1.15
MiRNA-based therapeutic intervention of cancer. J Hematol Oncol (2015) 1.14
Identification of acute myeloid leukaemia associated microRNA expression patterns. Br J Haematol (2008) 1.13
Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med (2013) 1.11
New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematology Am Soc Hematol Educ Program (2010) 1.11
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest (2013) 1.08
miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol (2013) 1.07
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal (2014) 1.06
miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J Oncol (2014) 1.04
Targeting PI3K/AKT/mTOR network for treatment of leukemia. Cell Mol Life Sci (2015) 1.04
The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell Death Differ (2013) 1.03
MicroRNAs as Haematopoiesis Regulators. Adv Hematol (2013) 1.03
The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. Leukemia (2012) 1.02
Aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation. Toxicol Sci (2011) 1.02
miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.01
Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways. FEBS Open Bio (2014) 1.01
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia (2014) 1.00
miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leuk Res (2014) 0.99
miR-9 is a tumor suppressor in pediatric AML with t(8;21). Leukemia (2013) 0.98
MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia (2013) 0.96
Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. Cancer Res (2014) 0.96
MicroRNA expression in acute myeloid leukemia. Curr Hematol Malig Rep (2009) 0.95
Monocyte chemoattractant protein-1-deficiency impairs the expression of IL-6, IL-1β and G-CSF after transient focal ischemia in mice. PLoS One (2011) 0.95
The MicroRNA-132 and MicroRNA-212 Cluster Regulates Hematopoietic Stem Cell Maintenance and Survival with Age by Buffering FOXO3 Expression. Immunity (2015) 0.94
MicroRNA29a regulates the expression of the nuclear oncogene Ski. Blood (2011) 0.94
Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol (2010) 0.94
Cyclin C regulates human hematopoietic stem/progenitor cell quiescence. Stem Cells (2010) 0.93
ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation. Blood (2015) 0.93
Prognostic value of miR-96 in patients with acute myeloid leukemia. Diagn Pathol (2014) 0.91
miR-638 regulates differentiation and proliferation in leukemic cells by targeting cyclin-dependent kinase 2. J Biol Chem (2014) 0.90
Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients. Biomark Med (2015) 0.90
MicroRNAs distinguish cytogenetic subgroups in pediatric AML and contribute to complex regulatory networks in AML-relevant pathways. PLoS One (2013) 0.90
Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease. Blood (2013) 0.90
Overexpression and knockout of miR-126 both promote leukemogenesis. Blood (2015) 0.88
Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia. Onco Targets Ther (2012) 0.87
The pathological role and prognostic impact of miR-181 in acute myeloid leukemia. Cancer Genet (2015) 0.87
Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia. PLoS One (2015) 0.87
High miR-24 expression is associated with risk of relapse and poor survival in acute leukemia. Oncol Rep (2015) 0.86
Dysregulation of miR-124-1 predicts favorable prognosis in acute myeloid leukemia. Clin Biochem (2013) 0.85
Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia (2015) 0.85
Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia. PLoS One (2013) 0.85
C/EBPa-mediated activation of microRNAs 34a and 223 inhibits Lef1 expression to achieve efficient reprogramming into macrophages. Mol Cell Biol (2014) 0.85
Acquired copy number alterations of miRNA genes in acute myeloid leukemia are uncommon. Blood (2013) 0.84
A miRNA Signature in Human Cord Blood Stem and Progenitor Cells as Potential Biomarker of Specific Acute Myeloid Leukemia Subtypes. J Cell Physiol (2015) 0.84
Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia. Int J Lab Hematol (2012) 0.84
Leukemia Stem Cell-Released Microvesicles Promote the Survival and Migration of Myeloid Leukemia Cells and These Effects Can Be Inhibited by MicroRNA34a Overexpression. Stem Cells Int (2016) 0.82
Expression and prognostic significance of hsa-miR-142-3p in acute leukemias. Neoplasma (2013) 0.82
Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections. Mycoses (2015) 0.82
Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients. Leuk Res (2013) 0.81
The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPα. Leukemia (2015) 0.81